ME Therapeutics Holdings Inc. announced that the Company is receiving advisory services and up to $50,000 in research and development funding from the National Research Council of Canada Industrial Research Assistance Program to support the preclinical testing of the company?s myeloid targeted prodrug candidates. The funding will support the manufacture and testing of the prodrug candidates in selected mouse cancer models.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.03 CAD | 0.00% | -18.59% | +235.83% |
1st Jan change | Capi. | |
---|---|---|
+235.83% | 69.25M | |
+51.85% | 57.87B | |
+40.83% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- METX Stock
- News ME Therapeutics Holdings Inc.
- ME Therapeutics Holdings Inc. Receives Funding Support for Preclinical Testing of Prodrug Candidates